DOP2014000004A - Formulaciones parenterales de vacunas contra los norovirus - Google Patents
Formulaciones parenterales de vacunas contra los norovirusInfo
- Publication number
- DOP2014000004A DOP2014000004A DO2014000004A DO2014000004A DOP2014000004A DO P2014000004 A DOP2014000004 A DO P2014000004A DO 2014000004 A DO2014000004 A DO 2014000004A DO 2014000004 A DO2014000004 A DO 2014000004A DO P2014000004 A DOP2014000004 A DO P2014000004A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- parenteral formulations
- vaccines against
- against norovirus
- norovirus
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Composiciones de vacuna parenterales de dosis individuales que comprenden mezclas de partículas tipo virus monovalentes de Norovirus. También se divulgan métodos para conferir una inmunidad protectora contra infecciones por Norovirus en un ser humano por administración de dichas composiciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506447P | 2011-07-11 | 2011-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2014000004A true DOP2014000004A (es) | 2014-10-31 |
Family
ID=47506489
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2014000004A DOP2014000004A (es) | 2011-07-11 | 2014-01-10 | Formulaciones parenterales de vacunas contra los norovirus |
DO2022000030A DOP2022000030A (es) | 2011-07-11 | 2022-02-04 | Formulaciones parenterales de vacunas contra los norovirus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000030A DOP2022000030A (es) | 2011-07-11 | 2022-02-04 | Formulaciones parenterales de vacunas contra los norovirus |
Country Status (29)
Country | Link |
---|---|
US (5) | US9801934B2 (es) |
EP (3) | EP3299030B1 (es) |
JP (2) | JP6208659B2 (es) |
KR (1) | KR102096937B1 (es) |
CN (3) | CN103874507A (es) |
AU (2) | AU2012282658B2 (es) |
BR (1) | BR112014000656A2 (es) |
CA (1) | CA2841356C (es) |
CL (1) | CL2014000082A1 (es) |
CR (2) | CR20190540A (es) |
DK (1) | DK3299030T3 (es) |
DO (2) | DOP2014000004A (es) |
EA (3) | EA035442B1 (es) |
EC (1) | ECSP14013201A (es) |
ES (2) | ES2926487T3 (es) |
GE (1) | GEP201706668B (es) |
HK (3) | HK1198136A1 (es) |
IL (1) | IL230356B (es) |
MA (1) | MA35414B1 (es) |
MX (1) | MX356586B (es) |
MY (1) | MY170746A (es) |
PE (1) | PE20140845A1 (es) |
PH (1) | PH12018501515B1 (es) |
PL (2) | PL2731621T3 (es) |
SG (1) | SG10201605644WA (es) |
TN (1) | TN2014000008A1 (es) |
UA (1) | UA117732C2 (es) |
WO (1) | WO2013009849A1 (es) |
ZA (2) | ZA201401012B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2601969T3 (pl) | 2006-09-29 | 2016-10-31 | Preparaty szczepionki przeciw norowirusowi | |
KR20150129042A (ko) | 2007-09-18 | 2015-11-18 | 다케다 백신즈 인코포레이티드 | 노로바이러스에 대한 보호면역반응을 제공하는 방법 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
EP3299030B1 (en) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
CN106103720A (zh) | 2013-10-03 | 2016-11-09 | 武田疫苗股份有限公司 | 自细胞系检测和除去弹状病毒的方法 |
WO2015093452A1 (ja) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
GB201703644D0 (en) | 2017-03-07 | 2017-04-19 | Elopak As | Improvements in or relating to toller mounting arrangements |
JP2020519666A (ja) * | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
EP3752185A1 (en) * | 2018-02-15 | 2020-12-23 | Icon Genetics GmbH | Immunogenic composition and vaccine for generating an immune response to norovirus |
WO2019231712A1 (en) * | 2018-05-29 | 2019-12-05 | Stc.Unm | Virus-like particle compositions and methods of using same |
CN109265542B (zh) * | 2018-09-27 | 2021-06-15 | 国药中生生物技术研究院有限公司 | 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用 |
AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
US20230285534A1 (en) | 2020-01-08 | 2023-09-14 | Bharat Biotech International Limited | Viral vaccine compositions and methods of preparations thereof |
CA3213547A1 (en) | 2021-03-29 | 2022-10-06 | Naoshi Fukushima | Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus |
WO2022246323A1 (en) | 2021-05-21 | 2022-11-24 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
WO1992016543A1 (en) | 1991-03-25 | 1992-10-01 | Genelabs Incorporated | NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs |
CA2133339A1 (en) | 1992-04-08 | 1993-10-09 | Jennifer S. Rota | Wild-type measles virus glycoproteins: vaccine and detection method therefor |
AU4851493A (en) | 1992-09-07 | 1994-03-29 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
CN1087176C (zh) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | 含有3-o脱酰基单磷酰脂a的疫苗制剂 |
US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
CZ336696A3 (en) | 1994-05-16 | 1997-07-16 | Merck & Co Inc | Isolated and purified proteins of papillomavirus and process for preparing thereof |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US5834015A (en) * | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
WO1998044944A2 (en) | 1997-04-08 | 1998-10-15 | Merck & Co., Inc. | Stabilized human papillomavirus formulations |
WO1998050071A1 (en) | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
EA200100236A1 (ru) | 1998-08-14 | 2001-08-27 | Мерк Энд Ко., Инк. | Способ очистки вирусных частиц, подобных вирусу папилломы человека |
WO2000035479A1 (en) | 1998-12-17 | 2000-06-22 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
KR20010093290A (ko) * | 1999-02-05 | 2001-10-27 | 폴락 돈나 엘. | 사람 파필로마바이러스 백신 제제 |
ES2398413T3 (es) | 1999-06-22 | 2013-03-19 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Kit de detección de SRSV |
JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス(nv)を認識するモノクローナル抗体 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
AU2003217413A1 (en) | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
CA2849556A1 (en) | 2002-04-11 | 2003-10-23 | Vu Truong-Le | Preservation of bioactive materials by freeze dried foam |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
AU2003237528A1 (en) | 2002-06-07 | 2003-12-22 | Kentucky Bioprocessing, Llc | Flexible vaccine assembly and vaccine delivery platform |
JP4598519B2 (ja) | 2002-06-20 | 2010-12-15 | サイトス バイオテクノロジー アーゲー | アジュバントとして使用するためのパッケージ化されたウィルス様粒子:調製法及び使用法 |
EP1594536B1 (en) | 2003-01-30 | 2009-03-25 | Novartis Vaccines and Diagnostics, Inc. | Adjuvanted influenza vaccine |
JP2006518748A (ja) | 2003-02-20 | 2006-08-17 | ベクトン・ディキンソン・アンド・カンパニー | 改良されたワクチン接種のための大気圧噴霧凍結乾燥によって作製される組換えブドウ球菌エンテロトキシンb(<sb>r</sb>seb)の粉末処方物 |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
WO2005030806A2 (en) | 2003-09-24 | 2005-04-07 | Montana State University | Norovirus monoclonal antibodies and peptides |
WO2005037223A2 (en) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
AU2005295438B2 (en) | 2004-10-20 | 2012-07-05 | Sanofi Pasteur Biologics, Llc | Vaccines against Japanese encephalitis virus and West Nile virus |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
JP2008526870A (ja) | 2005-01-05 | 2008-07-24 | フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン | 送達ビヒクル、生体作用活性物質およびウイルスワクチン |
US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
PT1868642E (pt) | 2005-03-18 | 2013-07-10 | Cytos Biotechnology Ag | Proteínas de fusão de alergénios de gato e suas utilizações |
JP2009501001A (ja) | 2005-06-01 | 2009-01-15 | ダウ グローバル テクノロジーズ インコーポレイティド | 多価ウイルス様粒子の製造 |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
EP2360175B1 (en) | 2005-11-22 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and Sapovirus virus-like particles (VLPs) |
JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスgiの高感度検出方法 |
US20080029915A1 (en) * | 2006-08-02 | 2008-02-07 | Courtoy Nv | Rotary tablet press |
PL2601969T3 (pl) | 2006-09-29 | 2016-10-31 | Preparaty szczepionki przeciw norowirusowi | |
SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
ES2559421T3 (es) * | 2007-03-14 | 2016-02-12 | Takeda Vaccines, Inc. | Purificación de partículas similares a virus |
AU2008299589B2 (en) | 2007-09-12 | 2014-06-26 | Australian Centre For Plant Functional Genomics Pty Ltd | Plant seed active transcriptional control sequences |
KR20150129042A (ko) | 2007-09-18 | 2015-11-18 | 다케다 백신즈 인코포레이티드 | 노로바이러스에 대한 보호면역반응을 제공하는 방법 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
ES2668836T3 (es) | 2008-08-08 | 2018-05-22 | Takeda Vaccines, Inc. | Partículas similivíricas que comprenden secuencias de aminoácidos de la cápside compuestas para reactividad cruzada potenciada |
EP2381959A1 (en) * | 2009-01-22 | 2011-11-02 | Pharmathene Inc. | Stable vaccine compositions and methods of use |
EA201171032A1 (ru) * | 2009-02-10 | 2012-02-28 | Новартис Аг | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами |
US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
SG182636A1 (en) * | 2010-01-21 | 2012-08-30 | Ligocyte Pharmaceuticals Inc | Targeted heterologous antigen presentation on calicivirus virus-like particles |
EA023397B1 (ru) * | 2010-05-26 | 2016-05-31 | Селекта Байосайенсиз, Инк. | Комбинированные вакцины с синтетическими наноносителями |
EP3299030B1 (en) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
EP3827838B1 (en) | 2015-12-16 | 2023-06-07 | The Walter and Eliza Hall Institute of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
EP3529359B1 (en) | 2016-10-18 | 2023-12-13 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes for use in therapy |
US20210230548A1 (en) | 2018-05-03 | 2021-07-29 | Board Of Regents, The University Of Texas System | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
EP3840778A1 (en) | 2018-08-20 | 2021-06-30 | Takeda Vaccines, Inc. | Vlp formulations |
AR117462A1 (es) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
AU2020221409A1 (en) | 2019-02-15 | 2021-09-02 | Editas Medicine, Inc. | Modified natural killer (NK) cells for immunotherapy |
-
2012
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/en active Active
- 2012-07-11 CA CA2841356A patent/CA2841356C/en active Active
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/zh active Pending
- 2012-07-11 PL PL12811916T patent/PL2731621T3/pl unknown
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-07-11 CR CR20190540A patent/CR20190540A/es unknown
- 2012-07-11 MX MX2014000411A patent/MX356586B/es active IP Right Grant
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/zh active Pending
- 2012-07-11 EA EA201792407A patent/EA035442B1/ru not_active IP Right Cessation
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/ko active IP Right Grant
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/pl unknown
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/en active Application Filing
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/da active
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/ja active Active
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/en active Pending
- 2012-07-11 ES ES17199372T patent/ES2926487T3/es active Active
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/zh active Pending
- 2012-07-11 EA EA201490258A patent/EA029470B1/ru not_active IP Right Cessation
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 EA EA202090699A patent/EA202090699A3/ru unknown
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/pt not_active Application Discontinuation
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/es active Active
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/en active Active
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/es active IP Right Grant
- 2012-11-07 UA UAA201401321A patent/UA117732C2/uk unknown
-
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
-
2014
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/es unknown
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/es unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/fr unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/es unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/es unknown
- 2014-11-21 HK HK14111772.5A patent/HK1198136A1/xx unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/zh unknown
- 2014-12-18 HK HK14112697.5A patent/HK1199202A1/xx unknown
-
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
-
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/ja active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
-
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515B1/en unknown
-
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
-
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/es unknown
-
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP14013201A (es) | Formulaciones parenterales de vacunas contra los norovirus | |
CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
CL2016001874A1 (es) | Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras. | |
MA44238A (fr) | Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r | |
MX2012009581A (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
MY197723A (en) | Vaccine compositions for the prevention of dengue virus infection | |
PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
MX2013013801A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
HK1206366A1 (en) | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes | |
CO6561819A2 (es) | Vectores para vacunas y método para potenciar respuestas inmunes | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
BR112015021523A2 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
WO2013033496A3 (en) | Laser adjuvants for enhancing immune response | |
BR112015002549A2 (pt) | regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas | |
MX2016002823A (es) | Metodos y composiciones para vacunas vectorizadas virales. | |
GT201400120A (es) | Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio | |
CR20150246A (es) | Composición inmunogénica contra la aeromonas hydrophila | |
UY38933A (es) | Vacuna de partículas tipo virus del chicunguña y métodos para su uso | |
NI201500109A (es) | Vacuna polivalente de proteína de fusión contra la influenza | |
BR112012022680A2 (pt) | métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina | |
UY35329A (es) | Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma. |